Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc. (NASDAQ: MNPR) is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States. Its pipeline includes ALXN1840, an oral once-daily investigational medicine in late-stage development, as well as MNPR-101, a humanized monoclonal antibody platform being paired with different radioisotopes for advanced solid tumors that express urokinase plasminogen activator receptor. The company is also advancing MNPR-101-Zr, a phase 1 imaging and dosimetry agent based on zirconium-89, and MNPR-101-Lu, a phase 1a radiotherapeutic using actinium-225. Monopar has collaboration arrangements with NorthStar and with Excel Diagnostics and Nuclear Oncology Center, and it also has a license agreement with Alexion related to ALXN1840 for Wilson disease. Founded in 2014, the company is headquartered in Wilmette, Illinois.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MNPR
|
$72.56
|
-24.9% Downside
|
Overvalued
|
$127.62
|
32.1% Upside
|
Undervalued
|
Good
|
0.0%
|
November 6, 2026
|
4.9x
|
648.6 M
|
508.4 M
|
0.0%
|
66.7%
|
93.1
|
68.3%
|
